Discover investment opportunities in Synthetic Biology Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Synthetic Biology Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Synthetic Biology Stocks using our Smart AI Filter.
7 stocks found for "Synthetic Biology Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
2.51 | ±100.0% | -1.1 | 0.00% | |||
1.01 | ±72.3% | -3.1 | 0.00% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
1.92 | ±68.6% | -1.9 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.99 | ±67.1% | -2.5 | 0.00% | |||
1.82 | ±67.7% | -15.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What makes synthetic biology stocks like DNA and CRSP appealing to growth investors?
A: Synthetic biology companies such as DNA and CRSP are appealing for growth investors due to their potential in revolutionizing industries like healthcare and agriculture. These stocks often focus on cutting-edge technologies like CRISPR and gene editing, which can lead to significant scientific breakthroughs and create new market opportunities.
Q: How might the performance of AMRS and TWST be influenced by trends in sustainability?
A: As synthetic biology companies, AMRS and TWST are positioned to benefit from sustainability trends by developing bio-based products that replace petroleum-derived materials. Changes in consumer preferences toward sustainable products may enhance demand for their innovations, potentially boosting financial performance.
Q: What are common risks associated with investing in gene editing companies like EDIT and NTLA?
A: Investing in gene editing companies such as EDIT and NTLA involves risks like high R&D costs, regulatory hurdles, and ethical concerns. Additionally, the technology is still emerging, which may result in variable returns due to market acceptance and competition.
Q: Do synthetic biology stocks like SYRS and SGMO offer competitive advantages in the pharmaceutical industry?
A: SYRS and SGMO derive competitive advantages from their specialized focus in synthetic biology, potentially allowing for novel drug development. Their cutting-edge research in genetic therapies can lead to proprietary treatments, attracting interest from larger pharmaceutical companies through partnerships or acquisitions.
Q: Can investing in VRTX provide stability in a volatile market environment?
A: VRTX, as an established biotechnology firm with profitable drug products, may provide relative stability in volatile markets. Its strong pipeline and existing revenue streams from approved medicines might offer some resilience against sector fluctuations.
Q: What role does innovation play in the potential success of synthetic biology companies like BEAM?
A: Innovation is crucial for BEAM's potential success, as the company's future relies on developing novel therapies using precision genetic editing technologies. Breakthrough innovations may enable them to address unmet medical needs and capture market share.
Amgen said it will spend more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California. It is the latest in a string of new U.S. investments by the pharmaceutical industry as President Donald Trump threatens to clamp down on the industry with tariffs on pharmaceuticals imported into the country.
Read moreOncolytics Biotech (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read more